June 14, 2024

Dear Colleague,

While the FDA continues to focus on protecting the public’s health, using science to guide our decisions, and facilitating access to critical medical products, we also recognize the work of our public health partners. As public health advocates, we know that your work to better our country is invaluable. Your partnership, knowledge and engagement in the public health space are appreciated.

Updates

• June 13, 2024 - FDA grants accelerated approval to repotrectinib for adult and pediatric patients with NTRK gene fusion-positive solid tumors
• June 13, 2024 - Remarks by Dr. Califf and Dr. Bumpus at the FDA Public Meeting: Optimizing FDA’s Use of and Processes for Advisory Committees
• June 13, 2024 - The Food and Drug Administration’s Inspection and Recall Process Should Be Improved To Ensure the Safety of the Infant Formula Supply
• June 12, 2024 - Combatting The Youth Vaping Epidemic By Enhancing Enforcement Against Illegal E-Cigarettes
• June 12, 2024 - Biden-Harris Administration Announces National Strategy to Reduce Food Loss and Waste and Recycle Organics
• June 11, 2024 - FDA Roundup
• June 10, 2024 - CDER Emerging Drug Safety Technology Program (EDSTP)
• June 10, 2024 - Justice Department and FDA Announce Federal Multi-Agency Task Force to Curb the Distribution and Sale of Illegal E-Cigarettes
• June 7, 2024 - FDA Roundup
• June 6, 2024 - FDA Releases 11th Annual Report on Drug Shortages

Spotlight!

Consumer Updates

Advisory Committees Give FDA Critical Advice and the Public a Voice

At the U.S. Food and Drug Administration, we rely on our many advisory committees to help us make sound decisions based on the best science available.

The FDA’s complex and multifaceted mission includes evaluating new medical devices and medicines, including vaccines and other therapies, to determine if they are safe and effective for their intended use. 

View all Official FDA Guidance Documents and other Regulatory Guidance
You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and comment period.

Webinars and Virtual Workshops

FDA Oncology Center of Excellence Presents: Conversations on Cancer: “Exploring Religious Literacy and Spirituality in Cancer Care”

July 10, 2024; 2:00 - 3:30 p.m. ET

This edition of the Conversations on Cancer public panel discussion series will start with a brief exploration of the difference between religion and spirituality.

Evaluating Immunosuppressive Effects of In Utero Exposure to Drug and Biologic Products

July 11 - 12, 2024

Day 1: Thu, Jul 11, 2024; 9:00 a.m. - 5:00 p.m. ET
Day 2: Fri, Jul 12, 2024; 9:00 a.m. - 1:00 p.m. ET

The FDA is announcing the following public workshop entitled " Evaluating Immunosuppressive Effects of In Utero Exposure to Drug and Biologic Products."

View Upcoming FDA Meetings, Conferences and Workshops
Public meetings involving the FDA: Upcoming events, past meetings, meeting materials, and transcripts

About Us

The Stakeholder Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, consumer groups, trade associations, patient advocacy organizations, think tanks/academia, and other stakeholders, in order to better inform our policy making process, identify policy hurdles or stakeholder misconceptions, and create strategic collaborations. For more information, please contact us at: FDAStakeholderEngagement@fda.hhs.gov.